Authum Investment Files Regulatory Disclosure for Approved ESOP Scheme 2025

Authum Investment & Infrastructure Limited has successfully concluded its postal ballot process and filed the mandatory regulatory disclosure under Regulation 30 of SEBI Listing Obligations. The company announced on December 15, 2025, that shareholders overwhelmingly approved the Employee Stock Option Scheme 2025 with 92.20% support, followed by the required regulatory filing with stock exchanges.

Postal Ballot Results

The postal ballot conducted through remote e-voting concluded on December 12, 2025, with impressive shareholder participation:

Voting Details:	Results
Total Shares Outstanding:	16,98,45,100
Total Votes Polled:	14,66,60,944 (86.35%)
Votes in Favor:	13,52,14,505 (92.20%)
Votes Against:	1,14,46,439 (7.80%)
E-voting Period:	Nov 13 - Dec 12, 2025

Both resolutions related to the Employee Stock Option Scheme 2025 received identical voting results, indicating unanimous shareholder support for the initiative.

ESOP Scheme Framework and Regulatory Filing

Following shareholder approval, the company submitted its regulatory disclosure to NSE and BSE under Regulation 30, providing comprehensive details of the approved scheme:

ESOP Parameters:	Details
Total Options Available:	Up to 5,00,000 options
Face Value per Share:	₹1.00
Eligible Recipients:	Company and subsidiary employees
Exercise Period:	Maximum 5 years from vesting
Implementation Route:	Direct route via NRC
Regulatory Compliance:	SEBI SBEB Regulations 2021

The scheme encompasses options for both company employees and eligible employees of subsidiary companies, with the Nomination and Remuneration Committee overseeing implementation and administration.

Key Terms and Exercise Framework

The regulatory filing reveals important operational details of the ESOP scheme:

Exercise Framework:	Specifications
Pricing Determination:	NRC discretion per applicable law
Accounting Compliance:	SEBI SBEB accounting standards
Share Issuance:	New equity shares (no secondary acquisition)
Vesting to Exercise:	Maximum 5-year window
Eligibility Criteria:	As defined in Scheme 2025

The exercise price will be determined by the Nomination and Remuneration Committee at the time of grant, ensuring compliance with applicable accounting standards and SEBI guidelines for employee share-based payments.

Compliance and Documentation

The postal ballot process was conducted with full regulatory compliance, with Mayank Arora & Co., Practicing Company Secretaries, serving as scrutinizer. The company's filing references SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155, demonstrating adherence to latest regulatory frameworks.

With 38,853 shareholders as of the November 7, 2025 cut-off date, the overwhelming approval reflects strong confidence in management's employee retention strategy. The scheme provides flexibility for future corporate actions while maintaining alignment with shareholder value creation objectives through proper regulatory oversight and transparent implementation processes.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.32%	+5.42%	+6.75%	+9.64%	+74.87%	+215.46%

Authum Investment & Infrastructure Limited (AIIL) has successfully completed a significant acquisition in Rivaara Labs Private Limited, as disclosed in a recent regulatory filing. The transaction, which concluded on October 30, 2025, marks a substantial investment in the healthcare sector for AIIL.

Transaction Details

The acquisition comprised multiple components:

Transaction Type	Number of Shares	Share Type
Subscription	360,000,000	CCPS
Purchase	158,420,000	Equity
Purchase	369,880,011	CCPS
Pending Purchase	40,000,000	CCPS

CCPS: Cumulative Compulsorily Convertible Participating Preference Shares

Key Points of the Acquisition

AIIL subscribed to 360 million CCPS issued by Rivaara Labs.
The company purchased 158.42 million equity shares and 369.88 million CCPS from existing shareholders of Rivaara Labs.
An additional 40 million CCPS are set to be acquired within the next 10 days, as per the agreed terms.
Following this transaction, AIIL is entitled to exercise 35.09% of the total voting rights in Rivaara Labs.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This transaction follows AIIL's earlier announcement on August 26, 2025, regarding the proposed acquisition.

Market Impact

This strategic move by Authum Investment & Infrastructure Limited represents a significant expansion in its investment portfolio. The acquisition of a substantial stake in Rivaara Labs may potentially impact AIIL's market position and financial performance in the coming quarters.

Investors and market watchers may want to keep a close eye on how this acquisition affects AIIL's business strategy and financial outcomes in the healthcare sector. The transaction underscores AIIL's commitment to diversifying its investments and potentially entering new markets.

As the remaining portion of the acquisition is expected to be completed within the next 10 days, further updates may be forthcoming. Stakeholders are advised to monitor official communications from the company for any additional information regarding this significant corporate action.